19.92 USD
▲-0.81+2.68%
盘后 19.40 0.00%
2026-08-03
市值
$1.48B
市盈率
—
EPS
-2.31
股息率
—
52 周区间
6.92 – 21.76
成交量
760.59K
Beta
0.86
目标价
28.33
52W 低 6.9252W 高 21.76
价格走势
公司简介
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase...